IMNM
Immunome, Inc.Healthcare·Biotechnology
$21.83
$2.1B market cap
Revenue
$0.0M
Free Cash Flow
$-113.6M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
2-Year Price History
$21.66+45.0%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -58.6 | -59.3 | -53.8 | -58.6 | -61.6 | -3.0 | 582.7 | 3.7 | 113.1 | -147.4% | -- | -- |
| Act | 2025-Q4 | 0.0 | -72.1 | -72.9 | -69.9 | -48.0 | -52.0 | -4.0 | 653.5 | 3.9 | 87.4 | -138.8% | -- | -- |
Valuation & Metrics
Market Stats
Price$21.83
Market Cap$2.1B
Enterprise Value$1.5B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-5.4%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-123.7M
Free Cash Flow$-113.6M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-143.1%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares18.7M
Days to Cover22.6
Change (vs Prior)+0.3%
Need at least 2 settlement dates for chart
Employees
Headcount131
Revenue / Employee$0
Gross Profit / Employee$-5,748
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
91.6%(+73.2% YoY)
181 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
23.1%(+18.5% YoY)
12 filers
Vanguard, iShares, SPDR
Market makers
0.2%(-0.3% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| FMR LLC | $371M | $13.82 | +$9.2M | +$286M | -0.0% | $1.89T |
| T. Rowe Price Investment Management, Inc. | $358M | $17.30 | +$64.3M | +$193M | -1.3% | $145.22B |
| BlackRock, Inc.Passive | $179M | $14.97 | +$12.5M | +$54.8M | -0.2% | $5.69T |
| Redmile Group, LLC | $122M | $13.83 | −$3.5M | +$4.3M | -5.9% | $1.51B |
| STATE STREET CORPPassive | $118M | $16.33 | +$33.5M | +$60.3M | -0.2% | $2.89T |
| PRIMECAP MANAGEMENT CO/CA/ | $105M | $12.59 | +$2.2M | +$30.1M | +0.4% | $127.01B |
| WELLINGTON MANAGEMENT GROUP LLP | $103M | $21.43 | +$83.1M | +$100M | -0.3% | $533.98B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $96.9M | $21.87 | +$96.9M | +$96.9M | — | $4.04T |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $89.7M | $18.47 | +$8.6M | +$76.3M | +0.3% | $13.60B |
| Enavate Sciences GP, LLC | $79.0M | $9.57 | −$25.3M | −$25.3M | +9.5% | $352M |
| PRICE T ROWE ASSOCIATES INC /MD/ | $62.5M | $14.16 | −$11.4M | −$4.6M | -0.2% | $864.93B |
| MORGAN STANLEY | $62.1M | $14.83 | +$24.8M | +$43.2M | -0.3% | $1.65T |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $56.0M | $13.96 | +$4.4M | +$17.9M | +2.3% | $1.61T |
| JPMORGAN CHASE & CO | $53.6M | $19.42 | −$1.7M | +$41.7M | -0.2% | $1.47T |
| SILVERARC CAPITAL MANAGEMENT, LLC | $40.5M | $21.65 | +$15.8M | +$40.5M | -0.2% | $843M |
| Sofinnova Investments, Inc. | $37.2M | $21.40 | +$1.8M | +$20.0M | +2.6% | $1.94B |
| Woodline Partners LP | $34.5M | $13.28 | +$0 | −$1.8M | -0.1% | $26.43B |
| MARSHALL WACE, LLP | $32.4M | $16.26 | +$16.3M | −$2.8M | +0.6% | $92.71B |
| PRINCIPAL FINANCIAL GROUP INC | $30.1M | $13.21 | −$603K | +$30.1M | -0.5% | $186.29B |
| READYSTATE ASSET MANAGEMENT LP | $28.5M | $12.40 | −$11.8M | +$23.6M | -0.9% | $962M |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-0.19%
avg per quarter
Holders (ex-self)
-0.23%
excl. this stock
Buyers (this Q)
-0.49%
114 buyers · $0.55B in
Sellers (this Q)
+0.95%
54 sellers · $0.19B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-7.5%
how holders react when this stock falls
On quiet Qs
+14.0%
−10% to +10% baseline
On rallies (+10%+)
+16.2%
how they react when this stock rises
Holders' portfolio flow this Q
-1.0%
outflows — trims may be forced
Sellers' portfolio flow this Q
-5.1%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-6.1%
Holder mid (any stock)
-4.4%
Holder rally (any stock)
-4.6%
Biggest decreases this quarter
Point72 Asset Management, L.P.exited−$151MEcoR1 Capital, LLCexited−$61.3MEnavate Sciences GP, LLC−$25.3Mα+9.5Jefferies Financial Group Inc.−$18.4Mα-1.6READYSTATE ASSET MANAGEMENT LP−$11.8Mα-0.9PRICE T ROWE ASSOCIATES INC /MD/−$11.4Mα-0.2Alyeska Investment Group, L.P.exited−$6.3MMonashee Investment Management LLCexited−$5.9MNeo Ivy Capital Managementexited−$4.1MRedmile Group, LLC−$3.5Mα-5.9
New buyers this quarter
Top-5 holders · 45.1%
FMR LLC--
T. Rowe Price Investment Management, Inc.--
BlackRock, Inc.--
Redmile Group, LLC--
STATE STREET CORP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
FMR LLC17.0MT. Rowe Price Investment Management, Inc.16.4MPoint72 Asset Management, L.P.—Redmile Group, LLC5.6MPRIMECAP MANAGEMENT CO/CA/4.8MWELLINGTON MANAGEMENT GROUP LLP4.7MEnavate Sciences GP, LLC3.6MEcoR1 Capital, LLC—DRIEHAUS CAPITAL MANAGEMENT LLC4.1MPRICE T ROWE ASSOCIATES INC /MD/2.9M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$33.005120.0%
Last Year (9 analysts)$33.115170.0%
Current Price$21.83
Analyst Ratings
12
Buy: 12Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$2.15M
9 txns · 3 insiders · 105,968 sh
Sells ($, 12mo)
$11.29M
5 txns · 4 insiders · 522,638 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-15 | BUY | BIENAIME JEAN JACQUES | director | 5,000 | $20.70 | $104K | $899K |
| 2026-04-02 | SELL | Higgins Jack | officer: Chief Scientific Officer | 9,438 | $21.64 | $204K | $476K |
| 2026-04-02 | SELL | Rosett Max | officer: Chief Financial Officer | 65,000 | $21.92 | $1.42M | $1.18M |
| 2026-03-27 | BUY | SIEGALL CLAY B | director, officer: President and CEO | 25,450 | $19.67 | $501K | $13.59M |
| 2026-03-23 | SELL | WAGENHEIM PHILIP | director | 28,200 | $20.65 | $582K | $7.04M |
| 2026-03-20 | SELL | WAGENHEIM PHILIP | director | 36,800 | $20.47 | $753K | $7.56M |
| 2026-03-11 | BUY | BIENAIME JEAN JACQUES | director | 1,000 | $21.55 | $22K | $828K |
| 2026-03-10 | BUY | BIENAIME JEAN JACQUES | director | 1,000 | $22.12 | $22K | $828K |
| 2025-12-30 | BUY | SIEGALL CLAY B | director, officer: President and CEO | 4,729 | $21.15 | $100K | $14.07M |
| 2025-12-22 | SELL | Barchas Isaac | director | 383,200 | $21.74 | $8.33M | $44.15M |
| 2025-12-19 | BUY | SIEGALL CLAY B | director, officer: President and CEO | 7,278 | $20.48 | $149K | $17.62M |
| 2025-12-19 | BUY | Tsai Philip | officer: Chief Technical Officer | 10,000 | $20.49 | $205K | $887K |
| 2025-12-18 | BUY | SIEGALL CLAY B | director, officer: President and CEO | 46,511 | $21.50 | $1000K | $18.34M |
| 2025-06-03 | BUY | BIENAIME JEAN JACQUES | director | 5,000 | $9.38 | $47K | $342K |
Order Flow (FINRA, ~3w lag)
17.4%retail+1.5pp
22.4%dark-4.4pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
IMMUNOME, INC.: Massive Dilution Engine Fueling Pre-Revenue Oncology R&D
Overall Risk
7/10
Fraud
2/10
Dilution
9/10
Insolvency
4/10
Earnings Overstated
3/10
Hidden Liabilities
7/10
Legal
3/10
Audit Warnings
5/10
Hidden Upside
6/10
Contextually Acceptable
8/10